From HandWiki - Reading time: 3 min
| Clinical data | |
|---|---|
| Trade names | Omegaven |
| Other names | Fish oil triglycerides |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Dependence liability | Intravenous |
| Drug class | Intravenous nutritional products |
| ATC code |
|
| Legal status | |
| Legal status | |
Fish oil, sold under the brand name Omegaven, is a fatty acid emulsion.[2] It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome.[2] It is rich in omega-3 fatty acids.[2]
Fish oil triglycerides was approved for use in the United States in July 2018,[3] and is available to people on the US market by prescription effective November 2018.[4]
In 2021, it was the 283rd most commonly prescribed medication in the United States, with more than 700,000 prescriptions.[5][6]
It has gained popularity in children in preference to the more commonly used intralipid after case reports that it reduced the risk of liver damage.[7]
A 2007, study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastroschisis, and intestinal atresia.[8]
A clinical trial exploring the use of fish oil as an adjunct to parenteral nutrition in surgical intensive care units at National Taiwan University Hospital completed in March 2007.[9]
Although the use of fish oil triglycerides in children in the United States is experimental, the use of it in adults in Europe is less controversial.[10] In European studies, fish oil triglycerides have been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[11] Fish oil triglycerides have also been associated with reduced mortality and antibiotic use during hospital stays.[12]